The Bio Report
A Class Action Suits Moves RICO From Mobsters to Medicine
Why It Matters
The case signals that powerful civil RICO tools can hold large drug manufacturers accountable for systematic safety fraud, potentially deterring future concealment of drug risks. For insurers, health funds, and patients, it underscores the financial stakes of undisclosed harms and may drive more rigorous transparency in drug safety reporting.
Key Takeaways
- •RICO used against Takeda, Eli Lilly for Actos fraud.
- •Court certified first national civil RICO class action in pharma.
- •Plaintiffs proved economic injury via regression analysis and internal documents.
- •Ninth Circuit affirmed proximate causation despite physicians as intermediaries.
- •RICO offers treble damages, fee shifting, and nationwide venue flexibility.
Pulse Analysis
The BioReport episode unpacks a groundbreaking civil RICO lawsuit targeting Takeda Pharmaceuticals and Eli Lilly over the diabetes drug Actos. Plaintiffs allege the companies concealed a bladder‑cancer risk, misleading regulators, physicians, and third‑party payers. By framing the conduct as a coordinated enterprise, the lawsuit leverages the Racketeer Influenced and Corrupt Organizations Act—originally designed for organized crime—to address large‑scale pharmaceutical fraud. The discussion highlights how RICO’s broad language and Supreme Court precedent have allowed its expansion into healthcare, enabling claims that go beyond traditional failure‑to‑warn or false‑claims theories.
A pivotal element of the case is the Ninth Circuit’s decision to certify a nationwide class action, marking the first successful civil RICO certification against a major drug maker. The court relied on common evidence—econometric regression analyses, internal communications, and peer‑reviewed studies—to demonstrate that third‑party payers suffered direct economic injury when Actos was prescribed without proper risk disclosure. The ruling also clarified proximate causation, rejecting the argument that physicians break the causal chain, and affirmed that foreseeable intermediaries do not shield defendants. This legal reasoning provides a template for future plaintiffs seeking to aggregate diffuse economic harms across the health‑care system.
Beyond the doctrinal significance, the episode explains why RICO is attractive to litigators. The statute mandates treble damages, dramatically amplifying potential recoveries, and includes fee‑shifting provisions that cover costly document‑intensive discovery. Moreover, RICO’s nationwide service of process and flexible venue rules simplify the logistics of large‑scale class actions. For pharmaceutical companies, the case signals that coordinated concealment of material risks can trigger powerful civil RICO liability, reshaping risk‑management strategies and encouraging greater transparency in drug safety communications.
Episode Description
RICO, the Racketeer Influenced and Corrupt Organizations Act, was originally designed to prosecute organized crime. Today, it sits at the center of a landmark class action against two of the world’s largest pharmaceutical companies over the diabetes drug Actos. Attorney Harrison James of Wisner Baum discusses Painters and Allied Trades District Council 82 Health Care Fund v. Takeda, a national civil RICO case alleging that Takeda and Eli Lilly carried out a coordinated, years-long scheme to downplay known bladder cancer risks. The complaint asserts that regulators, physicians, and third-party payers were misled, leading to billions of dollars in reimbursements for the drug. James discusses how RICO’s legal framework applies in the pharmaceutical context, what it took to secure class certification where similar efforts have failed, and the broader implications this case may hold for the industry.
Comments
Want to join the conversation?
Loading comments...